SEPTEMBER 11, 2023 What Happens to Medicine in Your Body? BY RACHEL CROWLEY

https://biobeat.nigms.nih.gov/2023/09/what-happens-to-medicine-in-your-body/?utm_medium=email&utm_source=govdelivery

How Do Medicines Work? BY RACHEL CROWLEY

https://biobeat.nigms.nih.gov/2023/10/how-do-medicines-work/?utm_medium=email&utm_source=govdelivery

FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer

Women, power, and cancer: a Lancet Commission Monday, November 13, 2023

https://event.on24.com/wcc/r/4254417/AB192BBF49789E49D22AF74ED0F8551F?partnerref=tlcom_lancetwebinarshub_lancetwomenpowercancer23 Women, power, and cancer: a Lancet Commission Nov 13, 2023 14:00 GMT / 9:00 EST Women, power, and cancer: a Lancet Commission was created to address urgent questions at the intersection of social inequality, cancer risk and outcomes, and the status of women in society. In this Lancet Webinar, authors of The Lancet Commission will summarise the key findings of the Commission, including cancer equity and gender transformative policies, cancer prevention in women, gender-responsive frameworks in the healthcare context, and the value of women in cancer economics.

Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00166-7/fulltext?dgcid=hubspot_email_conferencealerts_idweek23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278073512&_hsenc=p2ANqtz-9SjIsteKQckhBNN5pmk80V2aK_dHCvJ8COr1S9mxTV2nGSolsRguAJbVUBBh4C1TQmhnpfZ-GQ9hm93tDAh8cnwPixxw&utm_content=278073512&utm_source=hs_email

Directing vaccines to dendritic cells

Directing vaccines to dendritic cells Many cancer vaccines under investigation use mRNA to deliver key information to the immune system. But most of these trials do not effectively target dendritic cells, a key orchestrator of the immune response. Because dendritic cells display antigens on their surface, which activates other components of the immune system and sounds the alarm about a potential threat, they are an attractive target for cancer treatment strategies. With the ultimate goal of developing an improved vaccine strategy, a research team at Johns Hopkins University has designed a targeted, biodegradable nanoparticle that specifically delivers mRNA to dendritic cells. When evaluated in multiple mouse tumor models, treatment with the nanoparticles provided robust antitumor activity when combined with a type of therapy called immune checkpoint blockade. Their results were recently reported in the journal PNAS.

The Lancet Haematology in conversation with Meletios Dimopoulos on relapsed and refractory multiple myeloma

https://thelancethaematology.buzzsprout.com/1564352/13706562-meletios-dimopoulos-on-relapsed-and-refractory-multiple-myeloma?utm_campaign=update-lanhae&utm_medium=email&_hsmi=278408633&_hsenc=p2ANqtz--rVlgdFLgxerzq2nodtWXUfO79W4E3te_K-q4laEhIj-XTA_-TJrirAEXAClo3vf3mNZF7uWQzKlRWBo521qjVOFUi3Q&utm_content=278217566&utm_source=hs_email